Patents Issued in July 9, 2020
  • Publication number: 20200216489
    Abstract: Methods for synthesizing phycocyanin using a biological substance include first synthesizing the phycocyanin by receiving a source containing phycocyanin, forming a solution by adding the source to water, extracting the phycocyanin from the source containing phycocyanin, such as by lysing cell walls and adding chemical reagents to assist in the extraction process, separating the phycocyanin from the solution by using a filter, processing the solution through a centrifuge, and sterilizing the phycocyanin.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 9, 2020
    Inventor: Chenghui Zheng
  • Publication number: 20200216490
    Abstract: Provided herein are deuterated compounds and compositions useful in increasing PPAR? activity. The compounds have a formula where L5 comprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 17, 2019
    Publication date: July 9, 2020
    Applicant: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes
  • Publication number: 20200216491
    Abstract: Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.
    Type: Application
    Filed: December 24, 2019
    Publication date: July 9, 2020
    Inventors: Jianfeng Cai, Chuanhai Cao
  • Publication number: 20200216492
    Abstract: Presented herein, in certain embodiments, are compositions comprising synthetic polypeptides that specifically bind to MHC Class I.
    Type: Application
    Filed: November 9, 2017
    Publication date: July 9, 2020
    Inventors: Dirk ZAJONC, Bjoern PETERS, Soumya Govinda REMESH, Ge YING
  • Publication number: 20200216493
    Abstract: This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which n, R1, R1?, R2, R3, R4, R4?, and R5-R14 are defined in the specification. The compounds of formula (I) can be used to treat bacterial infection.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 9, 2020
    Applicant: FERRING B.V.
    Inventors: Antoine HENNINOT, Daniel William CARNEY
  • Publication number: 20200216494
    Abstract: The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 9, 2020
    Inventors: Stavros SELEMIDIS, Doug A. BROOKS, John O'LEARY
  • Publication number: 20200216495
    Abstract: This invention relates to the field of tau aggregation inhibitors. More specifically, the invention relates to amyloid therapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating aggregation associated conditions or diseases with certain peptides.
    Type: Application
    Filed: August 20, 2018
    Publication date: July 9, 2020
    Inventors: Shiho Tanaka, Ashley Wrght, James Treanor, Marcin Apostol, Matthew A.G. Graf
  • Publication number: 20200216496
    Abstract: The present invention relates to novel compounds of the formula (I), in which R is is hydrogen or hydroxy, that can be obtained by fermentation of the microorganism strain Corallococcus coralloides ST201330 (DSM 24989).
    Type: Application
    Filed: September 17, 2018
    Publication date: July 9, 2020
    Inventors: Heike Stump, Luigi Toti, Michael Kurz, Sabine Haag Richter, Diertmar Schummer
  • Publication number: 20200216497
    Abstract: An antimicrobial peptide has the amino acid sequence of SEQ ID NO: 1, except that i) the 1st and the 14th amino acids are deleted, ii) the 4th and the 8th amino acids are substituted with lysine (K), iii) the 7th amino acid is substituted with leucine (L), iv) the 9th amino acid is substituted with glycine (G) or lycine (K), and v) the 12th amino acid is substituted with serine (S) or lycine (K). A method for antimicrobial treatment in a subject including administering a pharmaceutically effective amount of the antimicrobial peptide to a subject.
    Type: Application
    Filed: September 21, 2018
    Publication date: July 9, 2020
    Inventors: Yoonkyung PARK, Min-Kyung KIM
  • Publication number: 20200216498
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 11, 2019
    Publication date: July 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
  • Publication number: 20200216499
    Abstract: Angiotensin (1-7) analogs are provided. The analogs contain one or more substitutions with non-natural amino acid cis-3-(aminomethyl)cyclobutanecarboxylic acid (ACCA). Also provided are methods of making such analogs and methods for using such analogs as therapeutic compositions to treat or prevent various diseases or conditions.
    Type: Application
    Filed: December 12, 2016
    Publication date: July 9, 2020
    Applicants: WAKE FOREST UNIVERSITY HEALTH SCIENCES, UNIVERSITY COLLEGE DUBLIN
    Inventors: Patricia E. Gallagher, E. Ann Tallant, Francesca Paradisi, Mark C. Chappell
  • Publication number: 20200216500
    Abstract: The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: July 9, 2020
    Applicant: FERRING B.V.
    Inventors: Elizabeth Serrano CHAVEZ, Helen SJOERGREN, Jette BOLL, Hayley REECE, Jonathan James LOUGHREY
  • Publication number: 20200216501
    Abstract: There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).
    Type: Application
    Filed: November 10, 2017
    Publication date: July 9, 2020
    Inventors: Mohammed Monzur MORSHED, Sai Kumar CHAKKA, Jennifer L. HICKEY, Manuel Perez VAZQUEZ, Andrew ROUGHTON, Adam Paul KAFAL, Narendrakumar B. PATEL
  • Publication number: 20200216502
    Abstract: The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.
    Type: Application
    Filed: September 24, 2018
    Publication date: July 9, 2020
    Inventors: Aurélie Albertini, Yves Gaudin, Hélène Raux, Laura Belot, Jovan Nikolic
  • Publication number: 20200216503
    Abstract: The present invention relates to a species of genus Pseudomonas identified as Pseudomonas BR11571, termed Candidatus Pseudomonas metallosolvens, having Accession Deposit Number DSM 32538.
    Type: Application
    Filed: September 17, 2018
    Publication date: July 9, 2020
    Inventors: Esther GABOR, Renate SCHULZE, Arnulf KLETZIN
  • Publication number: 20200216504
    Abstract: The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 9, 2020
    Inventors: VINCENT MARION, NIKOLAI PETROVSKY
  • Publication number: 20200216505
    Abstract: The present technology relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 9, 2020
    Inventors: Taylor SCHREIBER, George FROMM, Suresh DE SILVA
  • Publication number: 20200216506
    Abstract: The present invention provides methods and compositions of synthetic novel genes to manipulate signaling pathways of the immune system.
    Type: Application
    Filed: May 12, 2018
    Publication date: July 9, 2020
    Inventors: Jonathan C. Kagan, Yunhao Tan
  • Publication number: 20200216507
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: August 8, 2019
    Publication date: July 9, 2020
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING
  • Publication number: 20200216508
    Abstract: A therapeutic formulation containing mucin glycans derived from one or a number of nutritionally appropriate sources is described.
    Type: Application
    Filed: March 10, 2020
    Publication date: July 9, 2020
    Inventors: Angela L. Marcobal-Barranco, Justin L. Sonnenburg, Audrey M. Southwick
  • Publication number: 20200216509
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Application
    Filed: October 3, 2019
    Publication date: July 9, 2020
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • Publication number: 20200216510
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 9, 2020
    Inventors: Aimo KANNT, Maximilian BIELOHUBY, Ralf ELVERT, Michael WAGNER, Martin BOSSART, Torsten HAACK, Stephanie KEIL, Werner SEIZ
  • Publication number: 20200216511
    Abstract: Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido AsnA21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.
    Type: Application
    Filed: September 25, 2019
    Publication date: July 9, 2020
    Inventors: Jie Fei Ding, Aili Bo, Jack Yongfeng Zhang, Mary Zi-ping Luo, Zhongli Bao
  • Publication number: 20200216512
    Abstract: The present invention relates, in certain embodiments, to a fusion protein comprising a DEEP fusion tag and a target protein (e.g., protein of interest). In various other embodiments, the invention provides methods of producing a fusion protein comprising a DEEP fusion tag and a target protein, constructs comprising a nucleotide sequence encoding a DEEP fusion tag and a cloning site for introducing a nucleotide sequence encoding a target protein, and kits comprising such DNA constructs.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 9, 2020
    Inventors: Michael Hecht, Shlomo Zarzhitsky
  • Publication number: 20200216513
    Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.
    Type: Application
    Filed: July 3, 2018
    Publication date: July 9, 2020
    Inventors: Heidrun DEGEN, Silvia Goebel, Kristin ADLER, Martin UNGERER
  • Publication number: 20200216514
    Abstract: Provided herein are generalized extracellular molecule sensors (GEMSs) and polynucleotides encoding the GEMSs. Also provided herein are methods of making and using the GEMSs, such as therapeutic and diagnostic methods.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Martin Fussenegger, Leo Scheller, Tobias Strittmatter, David W. Fuchs, Daniel Bojar
  • Publication number: 20200216515
    Abstract: The present disclosure provides in vitro and in vivo methods for selecting a candidate CAR polynucleotide to be expressed in immune cells for its preferential capability to make immune cells proliferate in an antigen-dependent manner.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 9, 2020
    Inventors: Philippe DUCHATEAU, Anne-Sophie GAUTRON, Laurent POIROT
  • Publication number: 20200216516
    Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 9, 2020
    Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD
    Inventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
  • Publication number: 20200216517
    Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis.
    Type: Application
    Filed: September 18, 2019
    Publication date: July 9, 2020
    Inventor: M. Amin Arnaout
  • Publication number: 20200216518
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: October 18, 2019
    Publication date: July 9, 2020
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Publication number: 20200216519
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.
    Type: Application
    Filed: September 17, 2018
    Publication date: July 9, 2020
    Inventors: David Weiner, Ami Patel
  • Publication number: 20200216520
    Abstract: A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5? and 3? ITRs flank the expression cassettes and regulatory sequences.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 9, 2020
    Inventors: James M. Wilson, Anna Tretiakova
  • Publication number: 20200216521
    Abstract: This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriolysin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.
    Type: Application
    Filed: November 22, 2019
    Publication date: July 9, 2020
    Inventors: Mohammad Javad Aman, Rajan Prasad Adhikari
  • Publication number: 20200216522
    Abstract: In one aspect, antibodies that specifically bind to a human Tau protein are provided. In some embodiments, an anti-Tau antibody recognizes an epitope within residues 111-125 of full-length human Tau, an epitope within residues 251-270 and/or residues 346-360 of full-length human Tau, or an epitope within residues 186-205 of full-length human Tau. In some embodiments, an anti-Tau antibody specifically binds to phosphorylated human Tau, unphosphorylated human Tau, and/or multiple splice isoforms of human Tau. An anti-Tau antibody disclosed herein may also include one or two modified Fc polypeptides.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 9, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Lesley Ann Kane, Do Jin Kim, Joseph W. Lewcock, Suresh Poda, Rishi Rakhit, Rinkan Shukla, Adam P. Silverman
  • Publication number: 20200216523
    Abstract: The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 13, 2019
    Publication date: July 9, 2020
    Inventors: Paul DaSilva-Jardine, Hans de Haard
  • Publication number: 20200216524
    Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler
  • Publication number: 20200216525
    Abstract: Methods for treatment or prevention of medication overuse headache are provided. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler
  • Publication number: 20200216526
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Application
    Filed: April 18, 2019
    Publication date: July 9, 2020
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Publication number: 20200216527
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 9, 2020
    Applicant: Tillotts Pharma AG
    Inventor: Esther Maria FURRER
  • Publication number: 20200216528
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.
    Type: Application
    Filed: October 23, 2019
    Publication date: July 9, 2020
    Inventors: Christophe Frederic Jerome BLANCHETOT, Birgitte URSØ, Tine SKAK-NIELSEN, Malene BERTELSEN, Sebastian VAN DER WONING, Michael SAUNDERS, Johannes Joseph Wilhelmus DE HAARD
  • Publication number: 20200216529
    Abstract: The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Inventors: Jan Dominik HAAS, Jürgen KLATTIG, Nick Ernest René VANDEGHINSTE
  • Publication number: 20200216530
    Abstract: Monocytopoiesis is a hematological process that supplies the periphery with monocytes and subsequently with macrophages and monocyte-derived dendritic cells. Typically, monocytes circulate in the bloodstream for a very short time before undergoing apoptosis, however, stimulatory signals can trigger monocyte survival by inhibiting the apoptotic pathway, and thus contribute to the maintenance of the inflammatory response. Accordingly, there is a need for methods and pharmaceutical compositions for modulating monocytopoiesis. Now, the inventors show that type I interferons signaling promote the differentiation of monocyte-derived phagocytes at the level of their progenitors. Importantly, IFN-alpha and -beta were found to efficiently generate the development of monocyte-derived antigen-presenting cells while having no impact on the precursor activity of conventional dendritic cells. Accordingly, modulators of type I interferon (e.g.
    Type: Application
    Filed: July 24, 2018
    Publication date: July 9, 2020
    Inventors: Lionel POULIN, Corentin LASSEAUX, Mathias CHAMAILLARD
  • Publication number: 20200216531
    Abstract: The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.
    Type: Application
    Filed: July 16, 2018
    Publication date: July 9, 2020
    Inventors: Patrik Verstreken, Joseph McInnes, Lujia Zhou
  • Publication number: 20200216532
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Publication number: 20200216533
    Abstract: Methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 9, 2020
    Applicant: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • Publication number: 20200216534
    Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides, which can be used with adoptive cell transfer to target and kill cancers, that comprise a co-stimulatory signaling region having a mutated form of a cytoplasmic domain of CD28 that enhances CAR-T cell function, a mutated form of a cytoplasmic domain of 41BB that enhances nuclear factor kappaB (NF?B) signaling, or a combination thereof. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Also disclosed are immune effector cells co-expressing a CAR and one or more TRAF proteins. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a tumor associated antigen-expressing cancer that involves adoptive transfer of the disclosed immune effector cells.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 9, 2020
    Inventor: Marco L. DAVILA
  • Publication number: 20200216535
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Application
    Filed: November 14, 2019
    Publication date: July 9, 2020
    Inventors: Kang LI, Tong ZHANG, Jing SONG, Lanlan XU, Qi LIU, Hao PENG
  • Publication number: 20200216536
    Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 9, 2020
    Inventors: William Brondyk, Brett Chevalier, Juergen Horn, Madhusudan Natarajan
  • Publication number: 20200216537
    Abstract: CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 9, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Publication number: 20200216538
    Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 9, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Liang XIAO, Dengnian LIU, Hu LONG, Jiangjiang HU, Yamin CUI, Xiaoxi YUAN, Lichun WANG, Jingyi WANG